State of New Jersey Common Pension Fund D Decreases Holdings in Vaxcyte, Inc. (NASDAQ:PCVX)

State of New Jersey Common Pension Fund D reduced its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 26.1% during the second quarter, according to its most recent filing with the SEC. The fund owned 39,474 shares of the company’s stock after selling 13,955 shares during the quarter. State of New Jersey Common Pension Fund D’s holdings in Vaxcyte were worth $2,981,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in the stock. Parallel Advisors LLC raised its position in Vaxcyte by 155.3% in the fourth quarter. Parallel Advisors LLC now owns 411 shares of the company’s stock worth $26,000 after acquiring an additional 250 shares during the period. Fifth Third Bancorp purchased a new stake in shares of Vaxcyte during the 2nd quarter worth approximately $35,000. Fidelis Capital Partners LLC bought a new stake in shares of Vaxcyte in the 1st quarter worth approximately $37,000. J.Safra Asset Management Corp lifted its stake in Vaxcyte by 649.4% in the second quarter. J.Safra Asset Management Corp now owns 607 shares of the company’s stock valued at $46,000 after purchasing an additional 526 shares during the last quarter. Finally, Quest Partners LLC bought a new position in Vaxcyte during the second quarter valued at $70,000. Institutional investors own 96.78% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. BTIG Research upped their price target on Vaxcyte from $98.00 to $160.00 and gave the company a “buy” rating in a research report on Tuesday, September 3rd. Bank of America upped their price objective on shares of Vaxcyte from $101.00 to $140.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. Leerink Partners lifted their target price on shares of Vaxcyte from $106.00 to $153.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 3rd. Mizuho upped their price target on shares of Vaxcyte from $113.00 to $163.00 and gave the company an “outperform” rating in a research note on Tuesday, September 10th. Finally, Jefferies Financial Group lifted their price objective on shares of Vaxcyte from $108.00 to $129.00 and gave the company a “buy” rating in a research note on Tuesday, September 3rd. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $147.50.

Insider Activity at Vaxcyte

In other Vaxcyte news, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $75.64, for a total value of $1,134,600.00. Following the transaction, the chief executive officer now directly owns 478,888 shares in the company, valued at approximately $36,223,088.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Vaxcyte news, COO Jim Wassil sold 3,000 shares of Vaxcyte stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $76.34, for a total transaction of $229,020.00. Following the completion of the sale, the chief operating officer now owns 210,503 shares of the company’s stock, valued at $16,069,799.02. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Grant Pickering sold 15,000 shares of the company’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $75.64, for a total value of $1,134,600.00. Following the completion of the transaction, the chief executive officer now owns 478,888 shares of the company’s stock, valued at $36,223,088.32. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,283 shares of company stock valued at $7,271,218. Company insiders own 3.10% of the company’s stock.

Vaxcyte Trading Down 0.2 %

PCVX stock opened at $116.54 on Thursday. The firm has a 50 day moving average of $87.76 and a 200-day moving average of $75.76. The firm has a market capitalization of $12.68 billion, a P/E ratio of -27.23 and a beta of 0.97. Vaxcyte, Inc. has a 12 month low of $44.20 and a 12 month high of $119.50.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, August 6th. The company reported ($1.10) EPS for the quarter, beating the consensus estimate of ($1.14) by $0.04. During the same quarter in the prior year, the company earned ($0.70) earnings per share. Sell-side analysts predict that Vaxcyte, Inc. will post -4.33 EPS for the current year.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.